The global burden of hypertension exceeds 1.4 billion people
Top Cited Papers
- 1 June 2019
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 37 (6), 1148-1153
- https://doi.org/10.1097/hjh.0000000000002021
Abstract
In 2010, 1.4 billion people globally had hypertension, with 14% controlled to systolic blood pressure (SBP, mmHg) below 140, which contributes to 18 million cardiovascular deaths annually. Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140. In 2016, the Australian Guideline strongly recommended target SBP below 120 for adults at very high risk for CVE or aged above 75 years. In 2017 and 2018, the Canadian Guideline recommended automated office SBP (AOSBP) below 120 in adults at high risk and aged above 75 years (grade B). In 2017, the US Guideline recommended SBP below 130 for all adults (moderate-to-high risk class I; lower-risk grade IIb). In 2018, the European Guideline recommended SBP below 140 for all adults, and, if tolerated, a SBP range of 120–129 for adults aged below 65 years and 130–139 for adults aged at least 65 years (class I). The guidelines were variably influenced by Systolic blood PRessure INTervention trial and meta-analyses indicating fewer CVE when mean in-trial SBP was below 130 versus above 130. Clinicians considering lower SBP targets should be aware that: AOSBP preceded by 5-min rest is approximately 10–15 mmHg lower than usual office SBP; hypertensive patients with office SBP consistently versus intermittently below 140 have fewer CVE; benefits of mean office SBP or AOSBP below 120 remain unproven and could increase adverse events. Clinicians worldwide will do well to control SBP to below 140 in most hypertensive patients on most visits, which should lead to mean in-clinic SBP of 120–129.This publication has 33 references indexed in Scilit:
- The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT)Clinical Trials, 2014
- Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortalityJournal of the American Society of Hypertension, 2014
- Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary DiseaseThe American Journal of Medicine, 2014
- Automated Office Blood PressureCanadian Journal of Cardiology, 2012
- Comparative Assessment of Four Blood Pressure Measurement Methods in HypertensivesCanadian Journal of Cardiology, 2011
- Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertensionThe Lancet, 2010
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEuropean Heart Journal, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002